Application of NOD-like receptor family protein 3 as a marker in the preparation of reagents for diagnosing or monitoring immunosuppression in sepsis

By detecting the nucleic acid and protein expression levels of NOD-like receptor family protein 3 (NLRC3), the diagnostic and monitoring challenges of sepsis immunosuppression have been solved, enabling individualized treatment and resource optimization for sepsis patients and improving their survival rate.

CN116064764BActive Publication Date: 2024-11-22XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210899616.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-07-28
Publication Date
2024-11-22
Estimated Expiration
2042-07-28

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively identify and monitor the occurrence of sepsis immunosuppression, especially when the expression of anti-inflammatory cytokines increases during acute inflammatory responses. There is a lack of effective biomarkers for the diagnosis and monitoring of sepsis immunosuppression.

Method used

Using NOD-like receptor family protein 3 (NLRC3) as a biomarker, the levels of NLRC3 in peripheral blood mononuclear cells and tissue macrophages were detected. The nucleic acid transcription and protein expression levels of NLRC3 were monitored using methods such as conventional PCR, quantitative PCR, and ELISA to diagnose or monitor immunosuppression in sepsis.

Benefits of technology

By detecting NLRC3 levels, the occurrence of sepsis-induced immunosuppression can be accurately identified, providing individualized intervention and treatment plans, improving the cure rate of sepsis patients, providing a reference for the allocation of medical resources, and reducing mortality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003770493220000061
    Figure BDA0003770493220000061
  • Figure BDA0003770493220000071
    Figure BDA0003770493220000071
  • Figure HDA0003770493230000011
    Figure HDA0003770493230000011
Patent Text Reader

Abstract

The present invention relates to the field of biomedical technology, and in particular to the use of NOD-like receptor family protein 3 as a marker in the preparation of a reagent for diagnosing or monitoring sepsis immunosuppression. The present invention uses NLRC3 expression in peripheral blood mononuclear cells as a biomarker to prepare a reagent for predicting sepsis immunosuppression, and detects the transcription level of NLRC3 in peripheral blood mononuclear cells or tissue macrophages. Increased expression indicates immunosuppression in sepsis patients. Thus, individualized intervention therapy can be given to improve the rescue rate of sepsis immunosuppression, provide reference information for the rational selection of treatment methods and allocation of medical resources, and have important clinical application value for improving the prognosis of sepsis patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to the use of NOD-like receptor family protein 3 as a marker in the preparation of a reagent for diagnosing or monitoring sepsis immunosuppression. Background Art

[0002] Sepsis is a life-threatening organ dysfunction caused by host immune dysregulation against infection. It has always been the leading cause of death in intensive care units. Currently, there is no effective treatment except for traditional fluid resuscitation, anti-infection treatment, and symptomatic supportive therapy. Data in recent years have shown that regulating immune function is an important means to improve the mortality rate of sepsis. However, the timing of immune regulation intervention is one of the biggest problems at present. Therefore, monitoring changes in immune function in sepsis is the main way to reduce the mortality rate of sepsis. At present, the core of sepsis immune dysfunction, among which sepsis immunosuppression is the most important feature. It is generally believed that the immunosuppressive state occurs after the acute inflammatory response. However, in recent years, it has been observed that these states overlap or interweave, that is, in the excessive inflammatory stage of sepsis (i.e., a few hours to a few days after onset), the expression of immunosuppressive molecules or anti-inflammatory factors such as anti-inflammatory cytokines also increases, which brings great challenges to the clinical effective identification of the occurrence of sepsis immunosuppression. Therefore, the search for new markers is still a difficult problem that needs to be solved in the identification or diagnosis of sepsis immunosuppression.

[0003] NOD-like receptor family protein 3 (NLRC3) is a newly discovered, highly evolutionarily conserved intracytoplasmic pattern recognition receptor encoded by a gene on chromosome 16. This protein is highly expressed in immune cells such as monocytes / macrophages and plays an important role in regulating immune responses. Studies have shown that overexpression of NLRC3 protein can reduce the pro-inflammatory activity of bone marrow macrophages and human monocytes (THP-1), but there has been no report on the correlation between NLRC3 and sepsis or sepsis-induced immunosuppression. Summary of the invention

[0004] In view of this, the technical problem to be solved by the present invention is the use of NOD-like receptor family protein 3 (NLRC3) as a biomarker in a reagent or kit for diagnosing or predicting immunosuppression in sepsis.

[0005] The present invention provides the use of NLRC3 as a marker in preparing a reagent for diagnosing sepsis immunosuppression.

[0006] The present invention also provides the use of NLRC3 as a marker in the preparation of a reagent for monitoring the immune response ability of sepsis patients.

[0007] The present study showed that the NLRC3 mRNA level of monocytes in patients with sepsis was significantly higher than that in non-sepsis patients (P<0.01), and was negatively correlated with HLA-DR and TNF-α expression, which can reflect the immunosuppression state of sepsis. This shows that monocyte NLRC3 may be a marker for immunosuppression in sepsis. In addition, overexpression of NLRC3 protein can reduce the pro-inflammatory activity of bone marrow macrophages and human monocytes (THP-1). However, during acute inflammatory stimulation, the expression of NLRC3 was temporarily reduced, which suggests that changes in the expression of macrophage NLRC3 may reflect changes in the state of macrophage immune ability, and may be a new marker for monitoring the occurrence of immunosuppression in sepsis.

[0008] In the present invention, the reagent for diagnosing immunosuppression in sepsis and / or the reagent for monitoring the immune response ability of sepsis patients includes a reagent for detecting the level of NLRC3.

[0009] In the present invention, the NLRC3 level includes the nucleic acid transcription level and the protein expression level. More specifically, the NLRC3 level is the NLRC3 level in peripheral blood mononuclear cells and / or the NLRC3 level in macrophages in tissues. The detection of nucleic acid transcription level can be carried out by ordinary PCR method, or by quantitative PCR method, for example, by qPCR, rt-PCR method or digital PCR method, or by constant temperature amplification method, for example, by NASBA, RCA, HAD, RPA, LAMP, ERA or NERA method, which is not limited in the present invention. The detection of protein expression level can be carried out by ELISA, or by other protein expression level detection methods known in the art such as western blot, immunochromatography, immunoturbidimetry, etc., which is not limited in the present invention.

[0010] In an embodiment of the present invention, the reagent for detecting the NLRC3 level includes at least one of the following I) to IV):

[0011] 1), NLRC3 detection primers;

[0012] II), detection probe of NLRC3;

[0013] III), aptamers of NLRC3;

[0014] IV), antibodies against NLRC3.

[0015] In some embodiments, the NLRC3 level in the sample is detected by qPCR, and the primers used in the detection include the upstream primer shown in SEQ ID NO:1 and the downstream primer shown in SEQ ID NO:2.

[0016] In the embodiment of the present invention, the reagent for detecting the NLRC3 level is used to detect the transcription level of NLRC3 in peripheral blood monocytes or tissues or macrophages in tissues; the expression level of NLRC3 in the body fluid sample is negatively correlated with the immune function of monocytes and macrophages in sepsis immunosuppression.

[0017] The present invention also provides a method for detecting NLRC3 levels, which comprises detecting NLRC3 levels using the reagent described in the present invention.

[0018] On the one hand, the present invention shows that the occurrence of host immunosuppression in sepsis is related to NLRC3 in mononuclear macrophages. On the other hand, myeloid-specific NLRC3 knockout further confirms that the immune response ability of macrophages in sepsis-immunosuppressed mice is related to NLRC3 expression.

[0019] The present invention also provides the use of NLRC3 as a target in constructing a sepsis immunosuppression model.

[0020] In the present invention, the model is an animal model or a cell model. The animal includes fish, mouse, rabbit, sheep, dog, monkey, which is not limited in the present invention. The cell model includes human cells and / or animal cells, and may also include microbial cells, which is not limited in the present invention. In some embodiments, the cell is an immune cell, including but not limited to a macrophage; the animal model is a mammalian model, including but not limited to a mouse model.

[0021] Furthermore, the present invention also provides a reagent for constructing an animal and / or cell model, which comprises any one of the following i) to iii):

[0022] i) Reagents for knocking out or knocking down NLRC3;

[0023] ii), agents that inhibit NLRC3 activity;

[0024] iii) a substance that increases the level or activity of a NLRC3 inhibitor.

[0025] In the present invention, the reagents for constructing animal and / or cell models include: ① a lentivirus with NLRC3 transcript as the target sequence and capable of reducing the expression of NLRC3 gene expression products or gene transcription; ② a construct containing NLRC3 complementary sequences and capable of forming an activating molecule that promotes the expression of NLRC3 gene expression products or gene transcription after being transferred into the body; ③ immunosuppression-related cells and their differentiated cells after activating the NLRC3 gene sequence.

[0026] In some embodiments, the reagent for constructing a sepsis immunosuppression model comprises Cas9 mRNA or Cas9 Protein, and sgRNA targeting NLRC3, wherein the sgRNA targeting NLRC3 is as shown in SEQ ID NO: 5, or as shown in SEQ ID NO: 6.

[0027] In some embodiments, the reagents for constructing animal and / or cell models include a sequence of shRNA targeting NLRC3 as shown in SEQ ID NO:7.

[0028] The present invention also provides a method for constructing an animal and / or cell model, which comprises knocking out or knocking down NLRC3, reducing NLRC3 activity, or increasing the level or activity of a NLRC3 inhibitor using the reagent described in the present invention.

[0029] The present invention also provides an animal and / or cell model in which NLRC3 is knocked out or knocked down, or the activity of NLRC3 is inhibited, or the level or activity of NLRC3 inhibitors is increased. The present invention has found that the immune response ability of sepsis immunosuppressive macrophages with myeloid-specific NLRC3 knocked out or knocked down changes. The animal and / or cell model of the present invention can be used to simulate the occurrence and development of immunosuppression after sepsis.

[0030] The present invention uses NLRC3 expression in peripheral blood mononuclear cells as a biomarker to prepare a reagent for predicting immunosuppression in sepsis, and detects the transcription level of NLRC3 in peripheral blood mononuclear cells or tissue macrophages. Increased expression indicates immunosuppression in sepsis patients. Thus, individualized intervention therapy can be given to improve the rescue rate of immunosuppression in sepsis, provide reference information for the rational selection of treatment methods and allocation of medical resources, and have important clinical application value for improving the prognosis of sepsis patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 In the figure, A and B show the expression of HLA-DR in peripheral blood monocytes of patients with sepsis and non-sepsis, C shows the change of TNF-α in monocytes after LPS stimulation in vitro, and D shows the change of NLRC3 mRNA expression in the two groups of patients, where the data are expressed as mean ± standard error; compared with the Sham group, ***P<0.001;

[0032] Figure 2 In the figure, A shows the correlation analysis between HLA-DR and TNF-α expression changes in peripheral blood mononuclear cells of patients with sepsis, B shows the correlation analysis between NLRC3 and HLA-DR expression changes, and C shows the correlation analysis between NLRC3 and TNF-α expression changes;

[0033] Figure 3Figure 2. Changes of NLRC3 mRNA expression in peritoneal and alveolar macrophages after CLP. Data are presented as mean ± standard error. *P < 0.05 compared with the Sham group. n = 5

[0034] Figure 4 Shows the changes in NLRC3 expression after NLRC3 overexpression or downregulation vectors were transfected into macrophages, compared with the control group, ***P<0.001;

[0035] Figure 5 Figure 2 shows the effect of LPS secondary stimulation on TNF-α, IL-6 and IL-1β in immunosuppressive macrophages with stable expression and downregulation of NLRC3, where Naive: non-tolerant cells; Tolerant: immune paralyzed cells; data are expressed as mean ± standard error; Null Vector Naive Group comparison, *P<0.05; compared with NLRC3 Tolerant Group comparison, # P<0.05; n=5

[0036] Figure 6 Myeloid-specific NLRC3 knockout mice (NLRC3 ΔMAC ) and their littermate control mice (NLRC3 WT )Immune responses of peritoneal macrophages (PMs) and alveolar macrophages (AMs) after sepsis occurred, A-C are the expression levels of TNF-α, IL-6, and IL-1β in the supernatant of AMs, E-G are the expression levels of TNF-α, IL-6, and IL-1β in the supernatant of PMs; n=6 / group, *P<0.05**P<0.01***P<0.001, NS: no statistically significant difference. DETAILED DESCRIPTION

[0037] The present invention provides the use of NOD-like receptor family protein 3 as a marker in the preparation of a reagent for diagnosing or monitoring sepsis immunosuppression. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0038] The test materials used in the present invention are all common commercial products and can be purchased on the market. The present invention is further described below in conjunction with the embodiments:

[0039] Example 1 NLRC3 is upregulated in peripheral blood mononuclear cells of patients with sepsis and immunosuppression

[0040] Study population: According to the Sepsis 3.0 diagnostic criteria, whether sepsis was diagnosed or not was selected. Patients with sepsis and non-septic critically ill patients admitted to the comprehensive ICU of Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology were selected; Inclusion criteria: ① Meet the diagnostic criteria of sepsis in Sepsis 3.0; ② Age ≥ 18 years old; Exclusion criteria: ① Age < 18 years old; ② Uncooperative patients with mental illness; ③ Patients with incomplete clinical data. Peripheral blood samples were collected within 24 hours of admission to the ICU. 58 patients with sepsis and immunosuppression and 29 patients without sepsis were included in this study; The research plan was approved by the Medical Ethics Committee of this unit. Peripheral blood mononuclear cells (PBMCs) were separated by density gradient centrifugation (Ficoll method), and then prepared into cell suspensions with PRMI-1640 medium containing 10% fetal bovine serum and inoculated in plastic dishes. Monocytes were separated by adsorption separation (adherence method) in a 37℃, CO2 incubator for 60 minutes. The expression of HLA-DR on the surface of monocytes and the level of TNF-α in monocytes stimulated by LPS in vitro are used to judge whether the patients with sepsis are immunosuppressed. Figure 1 Middle A, Figure 1 Medium B and Figure 1 In this study, 35 patients with sepsis-related immunosuppression were included, and 29 non-septic critically ill patients were set up as the control group. Real-time PCR was used to detect the expression of NLRC3 mRNA in monocytes of each group. TaKaRa's RNAiso Plus reagent was used to extract total RNA, and 1 μg RNA was used to extract total RNA through TaKaRa's PrimeScript TM The cDNA was synthesized by RT-PCR kit, and the synthesized cDNA, primers and SYBR real-time PCR detection kit of TaKaRa Company were used as follows:

[0041] NLRC3 qPCR detection primers:

[0042] Forward primer: GTGCCGACCGACTCATCTG (SEQ ID NO: 1);

[0043] Reverse primer: GTCCTGCACTCATCCAAGC (SEQ ID NO: 2).

[0044] Table 1 PCR reaction system

[0045]

[0046] PCR reaction cycle system: pretreatment at 95.0°C for 30 seconds, then treatment at 95.0°C for 15 seconds and then at 60.0°C for 30 seconds as one cycle, cycle 40 times; melting curve 65°C-95°C, increase by 0.5°C / 10 seconds.

[0047] Depend on Figure 1 As shown in Figure D, the NLRC3 mRNA level in monocytes of patients with sepsis was significantly higher than that in patients without sepsis (P<0.01). This result suggests that monocyte NLRC3 may be a marker for immunosuppression in sepsis.

[0048] Example 2 Analysis of the correlation between NLRC3 expression in monocytes of sepsis patients and the immune status of patients

[0049] In Example 1 Figure 1 Middle A and Figure 1 Figure B shows that flow cytometry analysis of monocyte surface HLA-DR expression decreased. After the corresponding monocytes were stimulated by LPS in vitro, TNF-α in the monocyte supernatant was significantly reduced compared with non-septic patients, indicating that immunosuppression occurred in septic patients. The results of the correlation analysis between NLRC3 mRNA expression in monocytes of septic patients and the indicators of sepsis immunosuppression (HLA-DR and ΔTNF-α) are shown in Figure 2. Figure 2 As shown, the correlation is reflected by the correlation coefficient. Generally, |r|>0.95 means significant correlation; |r|≥0.8 means high correlation; 0.5≤|r|<0.8 means moderate correlation; 0.3≤|r|<0.5 means low correlation; and |r|<0.3 means extremely weak correlation, which is considered to be unrelated. Figure 2 Middle A shows that HLA-DR expression on the surface of monocytes is positively correlated with TNF-α release capacity (ΔTNF-α is the difference between LPS stimulation and no LPS stimulation) (r=0.6676); Figure 2 Medium B and Figure 2 Middle C shows that NLRC3 mRNA expression is negatively correlated with HLA-DR expression (r=-0.5451) and TNF-α release capacity (r=-0.7132). These results indicate that the occurrence of immunosuppression in patients with sepsis is associated with increased NLRC3 expression in monocytes, suggesting that NLRC3 can be used as an evaluation indicator for the occurrence of immunosuppression in sepsis.

[0050] Example 3 Overexpression of NLRC3 reduces the immune response ability of macrophages, while downregulation of NLRC3 expression increases the immune response ability of macrophages

[0051] To further evaluate the relationship between macrophage NLRC3 and the occurrence of immunosuppression in sepsis, primers were first designed based on the gene sequence of mouse NLRC3 (NM_001081280) in GenBank, and BamHI and AgeI restriction sites were added to the 5' ends of the upstream and downstream primers, respectively (primer sequences are shown in the table below). The NLRC3 overexpression lentiviral vector was used to construct a RAW264.7 macrophage cell line stably expressing NLRC3 (NLRC3);

[0052] Table 2

[0053]

[0054] At the same time, according to the gene sequence of mouse NLRC3 in GenBank and the results of preliminary experiments, the siRNA sequence GAGAACCACGGTCTGCACCATATTA (SEQ ID NO: 7) was selected as the NLRC3 interference target; according to the shRNA design principle, the bases of BamHI and EcoRI restriction sites were added to the 5' ends of its upstream and downstream primers respectively; the shNLRC3 stable down-regulated (shNLRC3) RAW264.7 macrophage cell line was constructed by shNLRC3 lentiviral vector; Real-time PCR detection found that ( Figure 4 ), compared with the control group, the expression of NLRC3 mRNA in the NLRC3 cell line was significantly increased; the expression of NLRC3 mRNA in the shNLRC3 cell line was significantly decreased (P<0.05);

[0055] Then, 100 ng / ml LPS was used to induce macrophage tolerance (Tolerant), and the sepsis immunosuppressive cell model was constructed. Then, 100 ng / ml LPS was used to stimulate the immunosuppressive macrophages for 12 h. Figure 5 As shown, after LPS stimulation, compared with Null Vector Naive Compared with the group, Null Vector Tolerant With NLRC3 Tolerant The levels of TNF-α and IL-6 in the group were significantly decreased compared with the Null Vector Tolerant With NLRC3 Tolerant Compared with the group, shNLRC3 Tolerant In the group cells, the levels of TNF-α, IL-1β, and IL-6 increased significantly; these results suggest that NLRC3 expression increases when the immune response capacity of macrophages decreases, and when the immune response capacity of macrophages increases, the NLRC3 expression level is low, and the NLRC3 expression level is expected to be an indicator for monitoring immunosuppression in sepsis.

[0056] Example 4 The relationship between the expression pattern of NLRC3 in peritoneal macrophages and alveolar macrophages of septic mice and the immunosuppression of sepsis

[0057] In order to evaluate the role of NLRC3 in diagnosing or monitoring the occurrence and development of immunosuppression in sepsis, an animal model of sepsis (cecal ligation and puncture) was constructed in an SPF sterile operating room: the experimental animals were anesthetized by intraperitoneal injection of 2% sodium pentobarbital. After anesthesia, a 1 cm longitudinal incision was made in the midline of the abdomen, the cecum was freed, and ligated with 4-0 silk thread at 1 / 2 of the ileocecal valve. A 20G puncture needle was perforated twice at the distal end of the ligation. After squeezing out a small amount of feces, the cecum was returned to the abdominal cavity, and the abdominal muscles and skin were sutured in layers; 0.8 mL of normal saline was injected subcutaneously on the back of the mouse for fluid resuscitation. The sham group was only exposed without puncture. Alveolar macrophages and peritoneal macrophages were collected at 24h, 48h and 72h after surgery, and LPS was stimulated in vitro. Real-time PCR was used to detect TNF-α expression; Figure 3 As shown in Figures A and B: Compared with the Sham group, the expression of TNF-α mRNA in alveolar and peritoneal macrophages in the CLP group was significantly reduced after LPS stimulation in vitro, which suggests that the peritoneal and alveolar macrophages in septic mice are immunosuppressed. Furthermore, Real-time PCR was used to detect the expression of NLRC3 mRNA in alveolar and peritoneal macrophages at 6h, 12h, 24h, 48h, 72h, 96h and 120h after surgery. Figure 3 As shown in C: CLP induced NLRC3 mRNA expression in alveolar macrophages, which first decreased and then increased. It decreased at 6 h and increased significantly at 24 h, 48 h, and 72 h, with statistically significant differences (P<0.05). Peritoneal macrophages are the first line of defense for lesions. Figure 3 The expression of NLRC3 mRNA in alveolar macrophages also showed a similar trend of change as shown in D. These results indicate that the occurrence of immunosuppression in sepsis is closely related to the increased expression of NLRC3 in macrophages, and NLRC3 can be used as an indicator to evaluate the occurrence of immunosuppression in sepsis.

[0058] Example 5 Effect of NLRC3 knockout on the immune response ability of macrophages in septic immunosuppressed mice

[0059] In order to further observe the occurrence of NLRC3 in vivo to detect the immunosuppression of sepsis, the method for constructing a myeloid cell-specific NLRC3 gene knockout mouse provided by the present invention comprises the following steps: (1) determining the target site of the gene to be knocked out in the mouse, first analyzing the structure of the NLRC3 gene, and finding that exon2-3 can be conditionally knocked out; designing sgRNA for the NLRC3 gene in the target site region, and after verification and screening, finding that the two sgRNAs sgRNA#5 and sgRNA#14 have stable effects, and their sequences are shown in SEQ ID No: 5 and SEQ ID No: 6, respectively, and the next step of the experiment is carried out.

[0060] Table 3

[0061] Guide 5‘→3’ (3')sgRNA#5 CAACATGATTACACACAAGTCCAGG(SEQ ID NO:5) (3')sgRNA#14 TTGGTTCAGAGTATGGCTGAGGG(SEQ ID NO:6)

[0062] ⑵ The active sgRNA and Cas9 mRNA or Cas9 Protein were co-injected or co-electroporated into the cytoplasm or nucleus of mouse fertilized eggs, and the fertilized eggs were transplanted into recipient mother mice for fertilization to obtain F0 generation conditional NLRC3 gene knockout mice; ⑶ The F0 generation NLRC3 gene knockout mice were cross-linked with Cre LysM Mice (purchased from Jackson Laboratory, USA) were hybridized to obtain the F1 generation LysM-Cre + / - NLRC3 loxp+ / - ; Then the F1 generation is self-fertilized to obtain the F2 generation: LysM-Cre + / - NLRC3 loxp / loxp / + / + Mice, namely myeloid cell-specific NLRC3 knockout mice (i.e., LysM Cre NLRC3 fl / fl , abbreviated as NLRC3 ΔMac ) and wild-type littermates or LysM-Cre - / - NLRC3 fl / fl Mice were used as control (i.e., NLRC3 fl / fl Abbreviated as NLRC3 WT );

[0063] Genetic mice were taken, and the cecal ligation and puncture (CLP) sepsis model and sham operation (sham) model were constructed respectively according to the method in Example 3. Alveolar macrophages and peritoneal macrophages were taken 48 hours after surgery, and LPS was stimulated in vitro. The expression of TNF-α, IL-6 and IL-1β in the cell supernatant was detected by enzyme-linked immunosorbent assay (ELISA); Figure 6 Shown: With NLRC3 WT Compared with mice, NLRC3 ΔMacThe expression of TNF-α and IL-6 in alveolar and peritoneal macrophages of septic mice was significantly increased, suggesting that the increased immune response capacity of macrophages in septic immunosuppressed mice was associated with decreased NLRC3 expression.

[0064] In summary: NLRC3 is used as a biomarker in the diagnosis or monitoring of sepsis immunosuppression. The increased immune response capacity of sepsis immunosuppressive macrophages is associated with low NLRC3 expression, while the reduced immune response capacity of macrophages is associated with high NLRC3 expression.

[0065] The present invention has verified each other in the diagnosis or monitoring of sepsis immunosuppression from different aspects such as clinical samples, animal experiments, and in vitro cells, and further confirmed that the immune response ability of macrophages in sepsis immunosuppression is related to NLRC3 expression. Therefore, the present invention believes that monitoring NLRC3 will have a better effect as a biomarker in the diagnosis or monitoring of sepsis immunosuppression.

[0066] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Use of a reagent for downregulating NLRC3 levels in the preparation of a drug for treating immunosuppression in sepsis, wherein the reagent for downregulating NLRC3 levels is siRNA, and the sequence of the siRNA is shown in SEQ ID NO:7.